Skip to content
OpenCapital
Get started

Utah Medical Products UTMD Gross Profit

Gross Profit at other companies

Avanos Medical logo
Avanos MedicalAVNS
$94.2M+4.9%

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Gross profit$5.3M-4.6%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Cash & equivalents$87.4M+4.9%
Total debt$210.0K—
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/E20.3×+6.4×
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity0×—
Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:GrossProfit.

The official record: Utah Medical Products’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's gross profit?
Utah Medical Products (UTMD) reported gross profit of $5.28M in Q1 2026.
How has Utah Medical Products's gross profit changed year-over-year?
Utah Medical Products's gross profit decreased by 4.6% year-over-year, from $5.54M to $5.28M.
What is the long-term trend for Utah Medical Products's gross profit?
Over 4 years (2021 to 2025), Utah Medical Products's gross profit has grown at a -8.2% compound annual growth rate (CAGR), from $30.92M to $22M.
What does gross profit mean?
Calculated as total revenue minus the direct costs of goods and services sold, representing the fundamental profitability of the company's core operations. It indicates how effectively the firm manages its production costs relative to its pricing power in the medical device market.